blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2763984

EP2763984 - 1-PYRAZOLYL-3-(4-((2-ANILINOPYRIMIDIN-4-YL)OXY)NAPTHTHALEN-1-YL)UREAS AS P38 MAP KINASE INHIBITORS [Right-click to bookmark this link]
Former [2014/33]1-PYRAZOLYL-3- (4- ( (2 -ANILINOPYRIMIDIN- 4 - YL) OXY) NAPTHTHALEN- 1 - YL) UREAS AS P38 MAP KINASE INHIBITORS
[2015/46]
StatusNo opposition filed within time limit
Status updated on  24.02.2017
Database last updated on 03.09.2024
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): IS		published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
Respivert Limited
50-100 Holmers Farm Way
High Wycombe, Buckinghamshire HP12 4EG / GB
[2014/33]
Inventor(s)01 / ITO, Kazuhiro
c/o Respivert Limited
Imperial College BioIncubator
Level 1
Bessemer Building
Imperial College London SW7 2AZ / GB
02 / CHARRON, Catherine Elisabeth
c/o Respivert Limited
Imperial College BioIncubator
Level 1
Bessemer Building
Imperial College London SW7 2AZ / GB
03 / KING-UNDERWOOD, John
Moorend Cottage
School Lane
Pendock Worcestershire GL19 3PW / GB
04 / ONIONS, Stuart Thomas
c/o Sygnature Chemical Services Ltd
Biocity Nottingham
Pennyfoot Street
Nottingham NG1 1GF / GB
05 / LONGSHAW, Alistair Ian
c/o Sygnature Chemical Services Ltd
Biocity Nottingham
Pennyfoot Street
Nottingham Nottinghamshire NG1 1GF / GB
06 / BROECKX, Rudy
c/o Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse / BE
07 / FILLIERS, Walter
c/o Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse / BE
08 / COPMANS, Alex
c/o Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse / BE
 [2014/33]
Representative(s)Teuten, Andrew John
Sagittarius IP
Marlow International
Parkway
Marlow SL7 1YL / GB
[N/P]
Former [2014/33]Teuten, Andrew John
Sagittarius IP
Three Globeside
Fieldhouse Lane
Marlow, Buckinghamshire SL7 1HZ / GB
Application number, filing date12772383.103.10.2012
[2016/16]
WO2012GB52445
Priority number, dateEP2011018368203.10.2011         Original published format: EP 11183682
EP2011018368803.10.2011         Original published format: EP 11183688
EP2012016839616.05.2012         Original published format: EP 12168396
EP2012016839516.05.2012         Original published format: EP 12168395
[2014/33]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013050757
Date:11.04.2013
Language:EN
[2013/15]
Type: A1 Application with search report 
No.:EP2763984
Date:13.08.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 11.04.2013 takes the place of the publication of the European patent application.
[2014/33]
Type: B1 Patent specification 
No.:EP2763984
Date:20.04.2016
Language:EN
[2016/16]
Search report(s)International search report - published on:EP11.04.2013
ClassificationIPC:C07D403/12, A61K31/4155, A61K31/506, C07D491/10
[2014/33]
CPC:
C07D403/12 (EP,CN,KR,US); A61K31/215 (US); A61K31/351 (US);
A61K31/4155 (US); A61K31/506 (KR,US); A61K31/513 (US);
A61K9/0073 (KR); A61P1/04 (EP); A61P1/18 (EP);
A61P11/00 (EP,KR); A61P11/02 (EP); A61P11/06 (EP);
A61P17/00 (EP); A61P17/02 (EP); A61P17/06 (EP);
A61P19/02 (EP); A61P27/02 (EP); A61P27/14 (EP);
A61P29/00 (EP); A61P3/10 (EP); A61P31/12 (EP);
A61P31/14 (EP,KR); A61P35/00 (EP); A61P35/04 (EP);
A61P37/08 (EP); A61P43/00 (EP); A61P7/00 (EP);
A61P9/04 (EP); C07D491/10 (EP,US); A61K9/0075 (EP);
C07B2200/13 (KR,US); Y02A50/30 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/33]
Extension statesBA07.04.2014
ME07.04.2014
TitleGerman:1-PYRAZOLYL-3-(4-((2-ANILINOPYRIMIDIN-4-YL)OXY)NAPTHTHALEN-1-YL)HARNSTOFFE ALS P38-MAP-KINASEHEMMER[2015/46]
English:1-PYRAZOLYL-3-(4-((2-ANILINOPYRIMIDIN-4-YL)OXY)NAPTHTHALEN-1-YL)UREAS AS P38 MAP KINASE INHIBITORS[2015/46]
French:1-PYRAZOLYL-3-(4-((2-ANILINOPYRIMIDIN-4-YL)OXY)NAPTHTHALEN-1-YL)URÉES COMME INHIBITEURS DE P38 MAP KINASE[2015/46]
Former [2014/33]1-PYRAZOLYL-3- (4-((2 -ANILINOPYRIMIDIN-4-YL-)OXY-)NAPTHTHALEN-1-)YL-HARNSTOFFE ALS P38-MAP-KINASEHEMMER
Former [2014/33]1-PYRAZOLYL-3- (4- ( (2 -ANILINOPYRIMIDIN- 4 - YL) OXY) NAPTHTHALEN- 1 - YL) UREAS AS P38 MAP KINASE INHIBITORS
Former [2014/33]L-PYRAZOLYL-3-(4-((2-ANILINOPYRIMIDIN-4-YL)OXY)NAPHTALÉN-1-YL)URÉES EN TANT QU'INHIBITEURS DE P38 MAP KINASE
Entry into regional phase07.04.2014National basic fee paid 
07.04.2014Designation fee(s) paid 
07.04.2014Examination fee paid 
Examination procedure26.07.2013Request for preliminary examination filed
International Preliminary Examining Authority: EP
07.04.2014Examination requested  [2014/33]
20.06.2014Amendment by applicant (claims and/or description)
02.06.2015Communication of intention to grant the patent
29.09.2015Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
05.11.2015Communication of intention to grant the patent
23.02.2016Fee for grant paid
23.02.2016Fee for publishing/printing paid
23.02.2016Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  02.06.2015
Opposition(s)23.01.2017No opposition filed within time limit [2017/13]
Fees paidRenewal fee
14.10.2014Renewal fee patent year 03
12.10.2015Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU03.10.2012
AL20.04.2016
BG20.04.2016
CY20.04.2016
CZ20.04.2016
EE20.04.2016
HR20.04.2016
LT20.04.2016
LV20.04.2016
MK20.04.2016
RO20.04.2016
RS20.04.2016
SI20.04.2016
SK20.04.2016
SM20.04.2016
NO20.07.2016
IS20.08.2016
MT31.10.2016
[2020/33]
Former [2018/46]HU03.10.2012
AL20.04.2016
BG20.04.2016
CY20.04.2016
CZ20.04.2016
EE20.04.2016
HR20.04.2016
LT20.04.2016
LV20.04.2016
MK20.04.2016
RO20.04.2016
RS20.04.2016
SI20.04.2016
SK20.04.2016
SM20.04.2016
NO20.07.2016
MT31.10.2016
Former [2018/38]HU03.10.2012
BG20.04.2016
CY20.04.2016
CZ20.04.2016
EE20.04.2016
HR20.04.2016
LT20.04.2016
LV20.04.2016
MK20.04.2016
RO20.04.2016
RS20.04.2016
SI20.04.2016
SK20.04.2016
SM20.04.2016
NO20.07.2016
MT31.10.2016
Former [2018/31]HU03.10.2012
CY20.04.2016
CZ20.04.2016
EE20.04.2016
HR20.04.2016
LT20.04.2016
LV20.04.2016
MK20.04.2016
RO20.04.2016
RS20.04.2016
SI20.04.2016
SK20.04.2016
SM20.04.2016
NO20.07.2016
MT31.10.2016
Former [2018/28]HU03.10.2012
CZ20.04.2016
EE20.04.2016
HR20.04.2016
LT20.04.2016
LV20.04.2016
MK20.04.2016
RO20.04.2016
RS20.04.2016
SI20.04.2016
SK20.04.2016
SM20.04.2016
NO20.07.2016
Former [2017/37]CZ20.04.2016
EE20.04.2016
HR20.04.2016
LT20.04.2016
LV20.04.2016
RO20.04.2016
RS20.04.2016
SI20.04.2016
SK20.04.2016
SM20.04.2016
NO20.07.2016
Former [2017/11]CZ20.04.2016
EE20.04.2016
HR20.04.2016
LT20.04.2016
LV20.04.2016
RO20.04.2016
RS20.04.2016
SK20.04.2016
SM20.04.2016
NO20.07.2016
Former [2017/10]CZ20.04.2016
EE20.04.2016
HR20.04.2016
LT20.04.2016
LV20.04.2016
RO20.04.2016
RS20.04.2016
SK20.04.2016
NO20.07.2016
Former [2017/09]CZ20.04.2016
EE20.04.2016
HR20.04.2016
LT20.04.2016
LV20.04.2016
RO20.04.2016
RS20.04.2016
NO20.07.2016
Former [2016/50]HR20.04.2016
LT20.04.2016
LV20.04.2016
RS20.04.2016
NO20.07.2016
Former [2016/46]LT20.04.2016
NO20.07.2016
Cited inInternational search[X]WO03072569  (BOEHRINGER INGELHEIM PHARMA [US]) [X] 1-16 * claims 1-13 *;
 [Y]WO2010067130  (RESPIVERT LTD, et al) [Y] 1-16 * claims 1-19 *;
 [Y]WO2010067131  (RESPIVERT LTD [GB], et al) [Y] 1-16 * claims 1-22 *;
 [Y]WO2010112936  (RESPIVERT LTD [GB], et al) [Y] 1-16 * claims 1-9 *;
 [Y]WO2011070368  (RESPIVERT LTD [GB], et al) [Y] 1-16* claims 1-25 *;
 [XP]WO2011158039  (RESPIVERT LTD [GB], et al) [XP] 1-16 * claims 1-21 *;
 [XP]WO2011158042  (RESPIVERT LTD [GB], et al) [XP] 1-16 * claims 1-38 *
by applicantWO2010067130
 WO2010112936
 WO2011070369
 WO2011158042
 WO2011158039
    - O'KEEFE, S.J. ET AL., J. BIOL. CHEM., (2007), vol. 282, no. 48, pages 34663 - 71
    - FITZSIMMONS, B.L. ET AL., NEUROREPORT, (2010), vol. 21, no. 4, pages 313 - 7
    - PETTUS, L.H.; WURZ, R.P., CURR. TOP. MED. CHEM., (2008), vol. 8, no. 16, pages 1452 - 67
    - SHMUELI, O. ET AL., COMPTES RENDUS BIOLOGIES, (2003), vol. 326, no. 10-11, pages 1067 - 1072
    - SMITH, S. J., BR. J. PHARMACOL., (2006), vol. 149, pages 393 - 404
    - HALE, K. K., J. IMMUNOL., (1999), vol. 162, no. 7, pages 4246 - 52
    - WANG, X. S. ET AL., J. BIOL. CHEM., (1997), vol. 272, no. 38, pages 23668 - 23674
    - COURT, N. W. ET AL., J. MOL. CELL. CARDIOL., (2002), vol. 34, no. 4, pages 413 - 26
    - MERTENS, S. ET AL., FEBS LETT., (1996), vol. 383, no. 3, pages 273 - 6
    - KUMA, Y., J. BIOL. CHEM., (2005), vol. 280, pages 19472 - 19479
    - CHUNG, F., CHEST, (2011), vol. 139, no. 6, pages 1470 - 1479
    - SMITH, S.J., BR. J. PHARMACOL., (2006), vol. 149, pages 393 - 404
    - UNDERWOOD, D.C. ET AL., AM. J. PHYSIOL., (2000), vol. 279, pages 895 - 902
    - NATH, P. ET AL., EUR. J. PHARMACOL., (2006), vol. 544, pages 160 - 167
    - IRUSEN, E. ET AL., J. ALLERGY CLIN. IMMUNOL., (2002), vol. 109, pages 649 - 657
    - LEE, M.R.; DOMINGUEZ, C., CURRENT MED. CHEM., (2005), vol. 12, pages 2979 - 2994
    - MERCADO, N. ET AL., MOL. PHARMACOL., (2011), vol. 80, no. 6, pages 1128 - 1135
    - PAPADOPOULOS, N.G.; PAPI, A.; PSARRAS, S.; JOHNSTON, S.L., PAEDIATR. RESPIR. REV, (2004), vol. 5, no. 3, pages 255 - 260
    - GRUNBERG, K.; SHARON, R.F. ET AL., AM. J. RESPIR. CRIT. CARE MED., (2001), vol. 164, no. 10, pages 1816 - 1822
    - WAT, D.; GELDER, C. ET AL., J. CYST. FIBROS, (2008), vol. 7, pages 320 - 328
    - LIU, M; WORLEY, S. ET AL., TRANSPL. INFECT. DIS, (2009), vol. 11, no. 4, pages 304 - 312
    - MESSAGE, S.D; LAZA-STANCA, V. ET AL., PNAS, (2008), vol. 105, no. 36, pages 13562 - 13567
    - GERNA, G.; PIRALLA, A. ET AL., J. MED. VIROL, (2009), vol. 81, no. 8, pages 1498 - 1507
    - OLIVER, B.G.; LIM, S. ET AL., THORAX, (2008), vol. 63, pages 519 - 525
    - WANG, J.H.; KWON, H.J.; YONG, J.J., THE LARYNGOSCOPE, (2009), vol. 119, no. 7, pages 1406 - 1411
    - PELEG, A.Y.; WEERARATHNA, T. ET AL., DIABETES METAB. RES. REV., (2007), vol. 23, no. 1, pages 3 - 13
    - KORNUM, J.B.; REIMAR, W. ET AL., DIABETES CARE, (2008), vol. 31, no. 8, pages 1541 - 1545
    - LUDWIG, S, SIGNAL TRANSDUCTION, (2007), vol. 7, pages 81 - 88
    - SHIN, Y.K.; LIU, Q. ET AL., J. GEN. VIROL., (2007), vol. 88, pages 13 - 18
    - EHRHARDT, C.; MARJUKI, H. ET AL., CELL MICROBIOL., (2006), vol. 8, pages 1336 - 1348
    - LUDWIG, S.; WOLFF, T. ET AL., FEBS LETT., (2004), vol. 561, no. 1-3, pages 37 - 43
    - SANDERSON, M.P.; LAU, C.W. ET AL., INFLAMM. ALLERGY DRUG TARGETS, (2009), vol. 8, pages 87 - 95
    - LAU, C. ET AL., J. LMMUNOL., (2008), vol. 180, no. 2, pages 870 - 880
    - BENTLEY, J.K.; NEWCOMB, D.C., J. VIROL., (2007), vol. 81, pages 1186 - 1194
    - INOUE, D.; YAMAYA, M., RESPIR. PHYSIOL. NEUROBIOL., (2006), vol. 154, no. 3, pages 484 - 499
    - SCHREIBER, S. ET AL., CLIN. GASTRO. HEPATOLOGY, (2006), vol. 4, pages 325 - 334
    - SHILO, Y., NATURE REVIEWS CANCER, (2003), vol. 3, pages 155 - 168
    - OLAHARSKY, A.J. ET AL., PLOS COMPUT. BIOL., (2009), vol. 5, no. 7, page E1000446
    - TIGHE, A. ET AL., BMC CELL BIOLOGY, (2007), vol. 8, page 34
    - PARGELLIS, C. ET AL., NATURE STRUCT. BIOL., (2002), vol. 9, no. 4, pages 268 - 272
    - FABIAN, M.A. ET AL., NATURE BIOTECHNOL., (2005), vol. 23, pages 329 - 336
    - MUEHLBAUER P.A.; SCHULER M.J., MUTATION RESEARCH, (2003), vol. 537, pages 117 - 130
    - MEDICHERLA S. ET AL., J. PHARMACOL. EXP. THER., (2008), vol. 324, no. 3, pages 921 - 9
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.